---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023488"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:31.210278+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# bioAffinity receives Nasdaq delisting notice; July CyPath Lung sales up 72% over prior monthly average

## Summary
- Nasdaq notified Company on Aug 7 that it failed to regain minimum bid price by Aug 6 and is ineligible for second 180-day period.
- Stockholders' equity of $1,439,404 at March 31, 2025 remains below the $2.5M minimum, adding a second delisting basis.
- Company intends to appeal by Aug 14, 2025; delisting scheduled for Aug 18 if appeal not filed.
- July completed tests for CyPath Lung surged 72% over the average of the first six months of 2025.
- Company reaffirms forecast of 3X year-over-year revenue for CyPath Lung; back-to-back record months in June and July.

## SEC filing metadata
- accession: 0001641172-25-023488
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000164117225023488/0001641172-25-023488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000164117225023488/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023488
- JSON: https://secwatch.observer/filing/0001641172-25-023488.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023488.txt

## Key facts
- Listing & Compliance Notices
  bioAffinity Technologies, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: ies will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August 18, 2025. In addition, as of the date hereof, the Company has not regained compliance with the Continued Listing Equity Requirement. As a result and pursuant to Listing Rule 5810(d)(2), this deficiency now serves as an additional basis for delisting of the Company’s securities. The Company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting and suspension of the Company’s securities pending the decision of the Panel. Hearings are typi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000164117225023488/0001641172-25-023488-index.htm
- Listing & Compliance Notices
  bioAffinity Technologies, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: ies will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August 18, 2025. In addition, as of the date hereof, the Company has not regained compliance with the Continued Listing Equity Requirement. As a result and pursuant to Listing Rule 5810(d)(2), this deficiency now serves as an additional basis for delisting of the Company’s securities. The Company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting and suspension of the Company’s securities pending the decision of the Panel. Hearings are typi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000164117225023488/0001641172-25-023488-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.